About Embolic Biotech Private Limited
Data last updated:
Embolic Biotech Private Limited is a private limited company based in Nsp-E Achole Road, Maharashtra, India. It operates in the pharmaceutical retail and distribution segment of the pharmaceuticals sector. It was incorporated on 06 May 2019 and has been in existence for over 7 years.
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN U33110MH2019PTC324996. Its GSTIN is 09AAFCE4768H1ZA (Uttar Pradesh).
The company has an authorised share capital of ₹10 Lakh and a paid-up capital of ₹1 Lakh. It is led by directors Kiran Singh and Meenu Srivastava.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Om Shi Shakti Bhawan Near Jeevan Chetna, Nsp – E Achole Road, Maharashtra, India – 401203.
As per the financials filed for FY 2024, the company reported a revenue of ₹1.51 Cr, a growth of 53% compared to the previous year. For the same year it recorded a net profit of ₹2.94 Lakh (net margin 1.9%) and EBITDA of ₹8.85 Lakh (EBITDA margin 5.9%). Revenue has grown at a compounded annual rate (CAGR) of 105% over three years.
For more details, the company can be reached via its website embolicbiotech.com.
- EmailLocked
- TelephoneLocked
- Website
- Social MediaLocked
- Registered AddressOm Shi Shakti Bhawan Near Jeevan Chetna, Nsp – E Achole Road, Maharashtra, India – 401203
- IndustryPharma, Pharmaceutical Retailers & Distributors
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
- One PDF report, delivered after checkout
Business Activity of Embolic Biotech Private Limited
The main business activity of Embolic Biotech is trade. In detail, this covers wholesale trading.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| G | Trade | G1 | Wholesale Trading | Locked |
Business activity turnover details
Turnover share and past changes in activity are in the company report.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Financials of Embolic Biotech Private Limited FY 2025 filings available
Embolic Biotech Private Limited reported revenue of ₹1.51 Cr (up 53% YoY) for FY 2024.
Compounded Annual Growth Rate (CAGR) of Embolic Biotech Private Limited
Revenue has grown at a compounded annual rate (CAGR) of 105% over three years, including 53% growth in the latest year. EBITDA rose 151% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary of Embolic Biotech Private Limited
| Metrics | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | •••• | •••• | •••• | •••• | •••• |
| Other Income | •••• | •••• | •••• | •••• | •••• |
| Total Revenue | •••• | •••• | •••• | •••• | •••• |
| Cost of Materials Consumed | •••• | •••• | •••• | •••• | •••• |
| Employee Benefit Expense | •••• | •••• | •••• | •••• | •••• |
| Finance Costs | •••• | •••• | •••• | •••• | •••• |
| Depreciation and Amortisation | •••• | •••• | •••• | •••• | •••• |
| Other Expenses | •••• | •••• | •••• | •••• | •••• |
| Total Expenses | •••• | •••• | •••• | •••• | •••• |
| EBITDA | ₹8.85 Lakh | •••• | •••• | •••• | •••• |
| Profit Before Tax | •••• | •••• | •••• | •••• | •••• |
| Tax Expense | •••• | •••• | •••• | •••• | •••• |
| Net Profit (PAT) | ₹2.94 Lakh | •••• | •••• | •••• | •••• |
| Balance Sheet | |||||
| Share Capital | •••• | •••• | •••• | •••• | •••• |
| Reserves and Surplus | •••• | •••• | •••• | •••• | •••• |
| Net Worth (Total Equity) | •••• | •••• | •••• | •••• | •••• |
| Long-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Short-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Trade Payables | •••• | •••• | •••• | •••• | •••• |
| Total Liabilities | •••• | •••• | •••• | •••• | •••• |
| Fixed Assets | •••• | •••• | •••• | •••• | •••• |
| Investments | •••• | •••• | •••• | •••• | •••• |
| Inventories | •••• | •••• | •••• | •••• | •••• |
| Trade Receivables | •••• | •••• | •••• | •••• | •••• |
| Cash and Bank Balance | •••• | •••• | •••• | •••• | •••• |
| Total Assets | •••• | •••• | •••• | •••• | •••• |
Financial Ratios of Embolic Biotech Private Limited
| Metrics | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 5.9% | •••• | •••• | •••• | •••• |
| Net Profit Margin | 1.9% | •••• | •••• | •••• | •••• |
| Return on Equity (ROE) | •••• | •••• | •••• | •••• | •••• |
| Return on Capital Employed (ROCE) | •••• | •••• | •••• | •••• | •••• |
| Return on Assets (ROA) | •••• | •••• | •••• | •••• | •••• |
| Liquidity and Debt | |||||
| Current Ratio | •••• | •••• | •••• | •••• | •••• |
| Quick Ratio | •••• | •••• | •••• | •••• | •••• |
| Debt-to-Equity Ratio | •••• | •••• | •••• | •••• | •••• |
| Interest Coverage Ratio | •••• | •••• | •••• | •••• | •••• |
| Efficiency and Growth | |||||
| Asset Turnover | •••• | •••• | •••• | •••• | •••• |
| Receivable Days | •••• | •••• | •••• | •••• | •••• |
| Payable Days | •••• | •••• | •••• | •••• | •••• |
| Inventory Days | •••• | •••• | •••• | •••• | •••• |
| Revenue Growth | •••• | •••• | •••• | •••• | •••• |
| Net Profit Growth | •••• | •••• | •••• | •••• | •••• |
Paid data: the figures shown as dots are available after purchase of the company report. Figures as filed with the MCA in Form AOC-4. The full year-wise statements and ratios of Embolic Biotech are in the company report.
Financial statements from FY 2020
Earlier years and trend charts are in the company report.
- Income statements
- Balance sheets
- Cash-flow statements
- Ratios and benchmarks
Verified entity values are shown only after access is granted.
Peer Comparison of Embolic Biotech Private Limited
Embolic Biotech Private Limited is compared with the companies closest to it by revenue in the same principal business activity (Wholesale Trading). Net profit, margin and employee counts of each company are in the company report.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Anjola Biotec Private Limited | ₹1.51 Cr (FY 2022) | •••• | •••• | 64.0% | •••• | Hyderabad, Telangana, India |
| Bicardia Pharmaceuticals Private Limited | ₹1.51 Cr (FY 2025) | •••• | •••• | 45.0% | •••• | Meerut, Uttar Pradesh, India |
| Saraswati Informatics Private Limited | ₹1.51 Cr (FY 2019) | •••• | •••• | 19.0% | •••• | Chandigarh, India |
| Quantist Growgrain Farmer Producer Company Limited | ₹1.51 Cr (FY 2025) | •••• | •••• | 188.0% | •••• | Nanded, Maharashtra, India |
| Manjusha Tie Up Private Limited | ₹1.51 Cr (FY 2025) | •••• | •••• | 3.0% | •••• | Kolkata, West Bengal, India |
| Embolic Biotech Private Limited this company | ₹1.51 Cr (FY 2024) | •••• | •••• | 53.0% | •••• | Nsp-E Achole Road, Maharashtra, India |
| Mats Pharma Private Limited | ₹1.51 Cr (FY 2022) | •••• | •••• | -43.0% | •••• | Kolkata, West Bengal, India |
| Nextnowo Private Limited | ₹1.51 Cr (FY 2023) | •••• | •••• | -62.0% | •••• | Mumbai, Maharashtra, India |
| Mel Floorings Private Limited | ₹1.51 Cr (FY 2025) | •••• | •••• | -8.0% | •••• | Ernakulam, Kerala, India |
| Rishi-Angira Kisan Producer Company Limited | ₹1.51 Cr (FY 2025) | •••• | •••• | -16.0% | •••• | Baran, Rajasthan, India |
| Decorma Glass India Private Limited | ₹1.51 Cr (FY 2024) | •••• | •••• | 220.0% | •••• | Bhiwadi, Rajasthan, India |
Peers are the five companies nearest above and the five nearest below Embolic Biotech by revenue in the same principal business activity (Wholesale Trading), from the latest filed financials of each company. Net profit, margin and employee counts of each peer are in the company report.
Auditor Details of Embolic Biotech Private Limited
Embolic Biotech Private Limited is audited by CHAUDHARY VINOD & COMPANY for the financial year 2023.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| CHAUDHARY VINOD & COMPANY | Locked | Locked | Locked |
Complete auditor history
Appointment and cessation dates and past auditor changes are in the company report.
- Appointment status
- Appointment dates
- Cessation dates
- Auditor changes
Verified entity values are shown only after access is granted.
Board of Directors of Embolic Biotech Private Limited
Embolic Biotech has 2 directors on record. No former directors are listed.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Kiran Singh | Director | 06 May 2019 | 7 Years 5 Months | Current |
| Meenu Srivastava | Director | 06 May 2019 | 7 Years 5 Months | Current |
Ownership and Shareholding of Embolic Biotech Private Limited
Shareholding and ownership data
Promoter, institutional, public and beneficial ownership figures are in the company report.
- Ownership categories
- Historical changes
- Group structure
- FII and DII holdings
Verified entity values are shown only after access is granted.
Charges & Borrowings of Embolic Biotech Private Limited
Embolic Biotech Private Limited does not have any charges (loans) registered with the Registrar of Companies.
Employees and EPFO Compliance at Embolic Biotech Private Limited
Embolic Biotech Private Limited has a workforce of 0 employees as of Apr 09, 2024.
Employee and EPFO history
Monthly headcount, contribution history and filing status are in the company report.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
Recent Activity on Embolic Biotech Private Limited
Embolic Biotech Private Limited has 2 board changes on record since 2019: 2 appointments. The latest: Kiran Singh was appointed as Director on 06 May 2019.
Credit Ratings, Litigation & Regulatory Alerts for Embolic Biotech Private Limited
Credit ratings, litigation, and regulatory alerts
Credit ratings, court records and regulatory alerts are in the company report.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
MSME Payment Delays by Embolic Biotech Private Limited
MSME payment history
Amounts due to small suppliers, the reasons given and MSME-1 filings are in the company report.
- Outstanding amounts
- Delay periods and reasons
- MSME-1 filing history
- Vendor payment signals
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Embolic Biotech Private Limited
Corporate group structure
Parent, subsidiary, associate and joint venture records with holdings are in the company report.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
GST Compliance of Embolic Biotech Private Limited
Embolic Biotech has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 09AAFCE4768H1ZA | Uttar Pradesh | Active | 28 Aug 2019 |
GST registrations and filing compliance
State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Embolic Biotech Private Limited
MCA filings and documents
Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Embolic Biotech Private Limited
Embolic Biotech is an active private limited company based in Nsp-E Achole Road, Maharashtra, India. The company works in pharmaceutical retailers and distributors, within the pharma industry. It was incorporated on 06 May 2019 (7+ years old) and is registered under CIN U33110MH2019PTC324996.
Embolic Biotech reported revenue of ₹1.51 Cr for FY 2024 (up 53% YoY).
Embolic Biotech has 2 current directors:
- Kiran Singh - Director
- Meenu Srivastava - Director
Embolic Biotech reported a net profit of ₹2.94 Lakh (net margin 1.9%) and EBITDA of ₹8.85 Lakh (EBITDA margin 5.9%) for FY 2024, as per its filed financial statements.
The compounded annual growth rate (CAGR) of the revenue of Embolic Biotech is 105% over three years. In the latest year (FY 2024) revenue rose 53%. CAGR is the steady yearly rate that links the first and the last year.
The GSTIN of Embolic Biotech is 09AAFCE4768H1ZA, registered in Uttar Pradesh.
The CIN (Corporate Identification Number) of Embolic Biotech is U33110MH2019PTC324996. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Embolic Biotech was incorporated on 06 May 2019, making it 7+ years old. It is registered with the Registrar of Companies, Mumbai.
The peers of Embolic Biotech by revenue are Anjola Biotec Private Limited, Bicardia Pharmaceuticals Private Limited, Saraswati Informatics Private Limited, Quantist Growgrain Farmer Producer Company Limited, Manjusha Tie Up Private Limited and 5 more, all in the same principal business activity (Wholesale Trading).
Kiran Singh was appointed as Director on 06 May 2019. Meenu Srivastava was appointed as Director on 06 May 2019.
Embolic Biotech can be reached through the website embolicbiotech.com. Its registered office is in Nsp-E Achole Road, Maharashtra, India.